Description
Recombinant Human BCMA/TNFRSF17 Protein (His Tag) | PKSH033486 | Gentaur US, UK & Europe Disrtribition
Synonyms: Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269;TNFRSF17; BCM; BCMA
Active Protein: N/A
Activity: Recombinant Human BCMA is produced byour Yeast expression system and the target gene encoding Met1-Ala54 is expressed with a 6His tag at the C-terminus.
Protein Construction: Recombinant Human BCMA is produced byour Yeast expression system and the target gene encoding Met1-Ala54 is expressed with a 6His tag at the C-terminus.
Fusion Tag: C-His
Species: Human
Expressed Host: P.Pichia
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 6.9 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
Reconstitution: Please refer to the printed manual for detailed information.
Background: Tumor necrosis factor receptor superfamily; member 17 (TNFRSF17); also known as B cell maturation antigen (BCMA) or CD269 antigen; is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes; and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily; member 13b (TNFSF13BBAFF); and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members; and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-; TRAF6-; NIK-; and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
Research Area: Signal Transduction, Cancer, immunology,
